Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-26042

Läubli, H; Borsig, L (2009). Heparins attenuate cancer metastasis: are selectins the link? Cancer Investigation, 27(5):474-481.

[img]
Preview
Accepted Version
PDF
1283Kb

Abstract

Heparin is often used to prevent or treat thromboembolism in cancer patients. Clinical and experimental evidence suggest that heparin also has anti-cancer activities. Experimental evidence consistently supports the ability of heparin to attenuate metastasis. The potential anti-metastatic effects of heparin include the inhibition of cell-cell interactions or heparanase and modulation of growth factors and anticoagulant activity. Heparin inhibits selectin-mediated interactions of tumor cells with leukocytes, platelets and endothelial cells, which are likely to mediate the initial steps of hematogenous metastasis. Prospective clinical trials can be designed based on the insights obtained from experimental studies.

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Institute of Physiology
07 Faculty of Science > Institute of Physiology
DDC:570 Life sciences; biology
Language:English
Date:June 2009
Deposited On:19 Jan 2010 16:24
Last Modified:09 Jul 2012 06:04
Publisher:Informa Healthcare
ISSN:0735-7907
Additional Information:This is an electronic version of an article published in Cancer Investigation. 2009 Jun;27(5):474-81. Cancer Investigation is available online at http://informahealthcare.com/doi/abs/10.1080/07357900802647136
Publisher DOI:10.1080/07357900802647136
PubMed ID:19479484
Citations:Google Scholar™

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page